UBS AG’s Favorite Third Quarter Healthcare Stocks: JNJ, PFE, MRK

Wall St. Watchdog reveals information regarding UBS AG’s top holdings in the Healthcare sector for the quarter ending September 30th, 2011. The firm held 827 stocks in the Healthcare sector at the end of the quarter with an aggregate market value of $3.038 billion.

  • Johnson & Johnson (NYSE:JNJ): On 06/30/2011, UBS AG reported holding 8,886,171 shares with a market value of $591,108,065. This comprised 0.65% of the total portfolio. On 09/30/2011, UBS AG reported holding 6,674,187 shares with a market value of $425,078,961. This comprised 0.93% of the total portfolio. The net change in shares for this position over the two quarters is -2,211,984. About Company: Johnson & Johnson manufactures health care products and provides related services for the consumer, pharmaceutical, and medical devices and diagnostics markets. The Company sells products such as skin and hair care products, acetaminophen products, pharmaceuticals, diagnostic equipment, and surgical equipment in countries located around the world.
  • Pfizer Inc. (NYSE:PFE): On 06/30/2011, UBS AG reported holding 20,143,678 shares with a market value of $414,959,774. This comprised 0.46% of the total portfolio. On 09/30/2011, UBS AG reported holding 13,716,449 shares with a market value of $242,506,823. This comprised 0.53% of the total portfolio. The net change in shares for this position over the two quarters is -6,427,229. About Company: Pfizer Inc. is a research-based, global pharmaceutical company that discovers, develops, manufactures, and markets medicines for humans and animals. The Company’s products include prescription pharmaceuticals, non-prescription self-medications, and animal health products such as anti-infective medicines and vaccines.
  • Merck & Co. Inc. (NYSE:MRK): On 06/30/2011, UBS AG reported holding 10,240,287 shares with a market value of $361,379,738. This comprised 0.4% of the total portfolio. On 09/30/2011, UBS AG reported holding 6,728,843 shares with a market value of $220,033,171. This comprised 0.48% of the total portfolio. The net change in shares for this position over the two quarters is -3,511,444. About Company: Merck & Co., Inc. is a global pharmaceutical company that discovers, develops, manufactures, and markets a broad range of human and animal health products. Merck’s products include a treatment for elevated cholesterol, a treatment for male pattern hair loss, a preventive treatment for osteoporosis, a treatment for hypertension, and a treatment for allergic rhinitis.
  • Abbott Laboratories (NYSE:ABT): On 06/30/2011, UBS AG reported holding 5,216,112 shares with a market value of $274,471,808. This comprised 0.3% of the total portfolio. On 09/30/2011, UBS AG reported holding 4,187,051 shares with a market value of $214,125,786. This comprised 0.47% of the total portfolio. The net change in shares for this position over the two quarters is -1,029,061. About Company: Abbott Laboratories discovers, develops, manufactures, and sells a broad and diversified line of health care products and services. The Company’s products include pharmaceuticals, nutritional, diagnostics, and vascular products. Abbott markets its products worldwide through affiliates and distributors.
  • Bristol-myers Squibb Company (NYSE:BMY): On 06/30/2011, UBS AG reported holding 6,070,456 shares with a market value of $175,800,400. This comprised 0.19% of the total portfolio. On 09/30/2011, UBS AG reported holding 4,959,784 shares with a market value of $155,638,018. This comprised 0.34% of the total portfolio. The net change in shares for this position over the two quarters is -1,110,672. About Company: Bristol-Myers Squibb Company is a global biopharmaceutical company that discovers, develops, manufactures and sells pharmaceutical and nutritional products. The Company’s products and experimental therapies address cancer, heart disease, HIV/AIDS, diabetes, rheumatoid arthritis, hepatitis, organ transplant rejection and psychiatric disorders.
  • Teva Pharmaceutical Industries Limited (NASDAQ:TEVA): On 06/30/2011, UBS AG reported holding 3,543,128 shares with a market value of $170,849,636. This comprised 0.19% of the total portfolio. On 09/30/2011, UBS AG reported holding 3,365,902 shares with a market value of $125,278,877. This comprised 0.27% of the total portfolio. The net change in shares for this position over the two quarters is -177,226. About Company: Teva Pharmaceutical Industries Ltd. develops, manufactures and markets generic and branded human pharmaceuticals and active pharmaceutical ingredients. The Company produces antibiotics, oncological products, Alpha D3 for treatment of post-menopausal bone loss in women and Copaxone for treatment of multiple sclerosis. Teva develops novel drugs for diseases of the central nervous system.
  • Medtronic Inc. (NYSE:MDT): On 06/30/2011, UBS AG reported holding 5,391,361 shares with a market value of $207,729,133. This comprised 0.23% of the total portfolio. On 09/30/2011, UBS AG reported holding 3,650,569 shares with a market value of $121,344,920. This comprised 0.27% of the total portfolio. The net change in shares for this position over the two quarters is -1,740,792. About Company: Medtronic, Inc. develops therapeutic and diagnostic medical products. The Company’s principal products include those for bradycardia pacing, tachyarrhythmia management, atrial fibrillation management, heart failure management, heart valve replacement, malignant and non-malignant pain, and movement disorders. Medtronic’s products are sold worldwide.
  • Novartis Ag (NYSE:NVS): On 06/30/2011, UBS AG reported holding 2,230,827 shares with a market value of $136,325,839. This comprised 0.15% of the total portfolio. On 09/30/2011, UBS AG reported holding 2,121,751 shares with a market value of $118,330,054. This comprised 0.26% of the total portfolio. The net change in shares for this position over the two quarters is -109,076. About Company: Novartis AG manufactures pharmaceutical and consumer healthcare products. The Company produces pharmaceuticals for cardiovascular, respiratory and infectious diseases; oncology, neuroscience, transplantation, dermatology, gastrointestinal and urinary conditions, and arthritis; vaccines and diagnostics; vision, and animal health products.
  • Amgen Inc. (NASDAQ:AMGN): On 06/30/2011, UBS AG reported holding 3,496,973 shares with a market value of $204,048,369. This comprised 0.23% of the total portfolio. On 09/30/2011, UBS AG reported holding 2,015,833 shares with a market value of $110,790,180. This comprised 0.24% of the total portfolio. The net change in shares for this position over the two quarters is -1,481,140. About Company: Amgen Inc. discovers, develops, manufactures, and markets human therapeutics based on cellular and molecular biology. The Company focuses its research on secreted protein and small molecule therapeutics, with particular emphasis on neuroscience and cancer. Amgen concentrates on the areas of hematology, cancer, infectious disease, endocrinology, neurobiology, and inflammation.
  • Celgene Corporation (NASDAQ:CELG): On 06/30/2011, UBS AG reported holding 1,684,973 shares with a market value of $101,637,571. This comprised 0.11% of the total portfolio. On 09/30/2011, UBS AG reported holding 1,395,965 shares with a market value of $86,424,193. This comprised 0.19% of the total portfolio. The net change in shares for this position over the two quarters is -289,008. About Company: Celgene Corporation is a global biopharmaceutical company. The Company focuses on the discovery, development, and commercialization of therapies designed to treat cancer and immune-inflammatory related diseases.

(Note: Data regarding UBS AG’s stock holdings are sourced from whalewisdom.com. All data are assumed to be accurate.)

Advantage: Check out our interactive stock charts, fundamentals, Twitter stream, and more >>

Improve Your 2011 Financial Health: Join the winning team of stock pickers with Wall St. Cheat Sheet’s acclaimed premium newsletter>>